JDRF’s Artificial Pancreas Project (APP) is an effort to integrate two existing technologies – the continuous glucose monitor and the insulin pump – with software that would provide the right amount of insulin at the right time, which is one important function of the pancreas.
The JDRF partnership announced today with Animas Corporation, a Johnson & Johnson Company, is an important step on the path to the development of an artificial pancreas and a critical development in JDRF’s continued efforts to translate basic research into treatments and therapies that will improve the lives of people with type 1 diabetes. As part of the Artificial Pancreas Project, JDRF is working with researchers and companies around the world with the goal of having multiple versions of an artificial pancreas available to people with type 1 diabetes.
While today’s announcement focuses on the partnership’s role in development and commercialization of a first-generation automated diabetes management system, it is important to note that Congress and the National Institutes of Health have played significant roles in the research progress that has brought us to this point. Through funding provided by Congress for the Special Diabetes Program and regular NIH appropriations, the NIH supported the initial research leading to the development of continuous glucose monitors and is currently funding research aimed at refining the algorithms needed for an artificial pancreas.
No comments:
Post a Comment